These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 15005622)

  • 1. Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments.
    Emadi S; Liu R; Yuan B; Schulz P; McAllister C; Lyubchenko Y; Messer A; Sierks MR
    Biochemistry; 2004 Mar; 43(10):2871-8. PubMed ID: 15005622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolating recombinant antibodies against specific protein morphologies using atomic force microscopy and phage display technologies.
    Barkhordarian H; Emadi S; Schulz P; Sierks MR
    Protein Eng Des Sel; 2006 Nov; 19(11):497-502. PubMed ID: 16984950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease.
    Park JY; Lansbury PT
    Biochemistry; 2003 Apr; 42(13):3696-700. PubMed ID: 12667059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity.
    Emadi S; Barkhordarian H; Wang MS; Schulz P; Sierks MR
    J Mol Biol; 2007 May; 368(4):1132-44. PubMed ID: 17391701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
    Conway KA; Harper JD; Lansbury PT
    Nat Med; 1998 Nov; 4(11):1318-20. PubMed ID: 9809558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity.
    Liu R; Yuan B; Emadi S; Zameer A; Schulz P; McAllister C; Lyubchenko Y; Goud G; Sierks MR
    Biochemistry; 2004 Jun; 43(22):6959-67. PubMed ID: 15170333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterizing antibody specificity to different protein morphologies by AFM.
    Wang MS; Zameer A; Emadi S; Sierks MR
    Langmuir; 2009 Jan; 25(2):912-8. PubMed ID: 19090748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein.
    Zhou C; Emadi S; Sierks MR; Messer A
    Mol Ther; 2004 Dec; 10(6):1023-31. PubMed ID: 15564134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.
    El-Agnaf OM; Paleologou KE; Greer B; Abogrein AM; King JE; Salem SA; Fullwood NJ; Benson FE; Hewitt R; Ford KJ; Martin FL; Harriott P; Cookson MR; Allsop D
    FASEB J; 2004 Aug; 18(11):1315-7. PubMed ID: 15180968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of nitration on the structure and aggregation of alpha-synuclein.
    Uversky VN; Yamin G; Munishkina LA; Karymov MA; Millett IS; Doniach S; Lyubchenko YL; Fink AL
    Brain Res Mol Brain Res; 2005 Mar; 134(1):84-102. PubMed ID: 15790533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha-synuclein.
    Du HN; Tang L; Luo XY; Li HT; Hu J; Zhou JW; Hu HY
    Biochemistry; 2003 Jul; 42(29):8870-8. PubMed ID: 12873148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid self-assembly of alpha-synuclein observed by in situ atomic force microscopy.
    Hoyer W; Cherny D; Subramaniam V; Jovin TM
    J Mol Biol; 2004 Jun; 340(1):127-39. PubMed ID: 15184027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins.
    El-Agnaf OM; Irvine GB
    J Struct Biol; 2000 Jun; 130(2-3):300-9. PubMed ID: 10940234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease.
    Volles MJ; Lansbury PT
    Biochemistry; 2003 Jul; 42(26):7871-8. PubMed ID: 12834338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of human alpha-synuclein specific single chain antibodies.
    Maguire-Zeiss KA; Wang CI; Yehling E; Sullivan MA; Short DW; Su X; Gouzer G; Henricksen LA; Wuertzer CA; Federoff HJ
    Biochem Biophys Res Commun; 2006 Nov; 349(4):1198-205. PubMed ID: 16973126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural evidence for alpha-synuclein fibrils using in situ atomic force microscopy.
    Zhang F; Ji LN; Tang L; Hu J; Hu HY; Xu HJ; He JH
    Acta Biochim Biophys Sin (Shanghai); 2005 Feb; 37(2):113-8. PubMed ID: 15685368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. alpha-Synuclein is phosphorylated in synucleinopathy lesions.
    Fujiwara H; Hasegawa M; Dohmae N; Kawashima A; Masliah E; Goldberg MS; Shen J; Takio K; Iwatsubo T
    Nat Cell Biol; 2002 Feb; 4(2):160-4. PubMed ID: 11813001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro.
    Hoyer W; Cherny D; Subramaniam V; Jovin TM
    Biochemistry; 2004 Dec; 43(51):16233-42. PubMed ID: 15610017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NMR of alpha-synuclein-polyamine complexes elucidates the mechanism and kinetics of induced aggregation.
    Fernández CO; Hoyer W; Zweckstetter M; Jares-Erijman EA; Subramaniam V; Griesinger C; Jovin TM
    EMBO J; 2004 May; 23(10):2039-46. PubMed ID: 15103328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Forcing nonamyloidogenic beta-synuclein to fibrillate.
    Yamin G; Munishkina LA; Karymov MA; Lyubchenko YL; Uversky VN; Fink AL
    Biochemistry; 2005 Jun; 44(25):9096-107. PubMed ID: 15966733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.